Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor
Authors:
- Johan A. Den BoerJBJohan A. Den Boer
- Herman G.M. WestenbergHWHerman G.M. Westenberg
- 1 March 1992
- journal article
- clinical trial
- Published by Elsevier in European Neuropsychopharmacology
- Vol. 2 (1) , 21-29
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Effect of brofaromine and pargyline on human plasma melatonin concentrationsProgress in Neuro-Psychopharmacology and Biological Psychiatry, 1988
- Effect of a Serotonin and Noradrenaline Uptake Inhibitor in Panic Disorder; a Double-blind Comparative Study with Fluvoxamine and MaprotilineInternational Clinical Psychopharmacology, 1988
- The influence of acute and subchronic administration of various antidepressants on early morning melatonin plasma levels in healthy subjects: Increases following fluvoxamineJournal of Neural Transmission, 1987
- Melatonin and cortisol increase after fluvoxamine [letter]British Journal of Clinical Pharmacology, 1986
- Social Phobia, MVP, and Response to ImipramineJournal of Clinical Psychopharmacology, 1986
- Treatment of Social Phobia with AtenololJournal of Clinical Psychopharmacology, 1985
- Social Phobia: A Comparative Clinical StudyThe British Journal of Psychiatry, 1983
- The Treatment of Social PhobiaJournal of Nervous & Mental Disease, 1981
- Treatment of Phobic States with AntidepressantsThe British Journal of Psychiatry, 1970
- THE ASSESSMENT OF ANXIETY STATES BY RATINGPsychology and Psychotherapy: Theory, Research and Practice, 1959